{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:54Z","timestamp":1793973594437,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jhepr.2023.100991","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T05:46:22Z","timestamp":1703137582000},"page":"100991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-3126","authenticated-orcid":false,"given":"Bo Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-9681","authenticated-orcid":false,"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-3385","authenticated-orcid":false,"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hwan","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-9332","authenticated-orcid":false,"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-8795","authenticated-orcid":false,"given":"Boram","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-0494","authenticated-orcid":false,"given":"Joong-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100991_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.17998\/jlc.21.1.58","article-title":"Hepatocellular carcinoma in Korea: an analysis of the 2015 Korean nationwide cancer registry","volume":"21","author":"Yoon","year":"2021","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.jhepr.2023.100991_bib3","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100991_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100991_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase III non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100991_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase III trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100991_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100991_bib8","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100991_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100991_bib11","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa Ghassan","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2023.100991_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase III trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3350\/cmh.2022.0294","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3350\/cmh.2023.0076","article-title":"Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis","volume":"29","author":"Hur","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib20","first-page":"25","article-title":"External beam radiotherapy for hepatocellular carcinoma: a review of the current guidelines in the east and the west","volume":"21","author":"Yoon","year":"2021","journal-title":"J\u00a0Liver Cancer"},{"key":"10.1016\/j.jhepr.2023.100991_bib21","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity","volume":"4","author":"Lewis","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2023.100991_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1159\/000368018","article-title":"Considerations for radiation therapy in hepatocellular carcinoma: the radiation oncologists' perspective","volume":"32","author":"Yu","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhepr.2023.100991_bib23","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.18632\/oncotarget.23428","article-title":"Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2023.100991_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev oncology\/hematology"},{"key":"10.1016\/j.jhepr.2023.100991_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.6004\/jnccn.2021.7037","article-title":"Integration of systemic and liver-directed therapies for locally advanced hepatocellular cancer: harnessing potential synergy for new therapeutic horizons","volume":"19","author":"Bent","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jhepr.2023.100991_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081901","article-title":"Outcomes and toxicities of modern\u00a0combined modality therapy with atezolizumab plus bevacizumab and radiation therapy for hepatocellular carcinoma","volume":"14","author":"Manzar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2023.100991_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jhepr.2023.100991_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5009\/gnl19024","article-title":"2018 Korean liver cancer association-national cancer center Korea practice guidelines for the management of hepatocellular carcinoma","volume":"13","year":"2019","journal-title":"Gut and liver"},{"key":"10.1016\/j.jhepr.2023.100991_bib31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol Cel"},{"key":"10.1016\/j.jhepr.2023.100991_bib32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US food and drug administration database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase II trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3350\/cmh.2020.0038","article-title":"Stereotactic body radiation therapy for small (<\/=5 cm) hepatocellular carcinoma not amenable to curative treatment: results of a single-arm, phase II clinical trial","volume":"26","author":"Yoon","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100991_bib35","first-page":"1","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"23","year":"2023","journal-title":"J\u00a0Liver Cancer"},{"key":"10.1016\/j.jhepr.2023.100991_bib36","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","article-title":"Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus","volume":"29","author":"Hu","year":"2023","journal-title":"Clin Cancer Res\u202f: official J Am Assoc Cancer Res"},{"key":"10.1016\/j.jhepr.2023.100991_bib37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2023.100991_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhepr.2023.100991_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923003221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923003221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:33:12Z","timestamp":1762900392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923003221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2589555923003221"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100991","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100991"}}